25-11-2025 15:10 via drugs.com

Pill Form of Semaglutide Fails to Slow Alzheimer's in Large Trial

TUESDAY, Nov. 25, 2025— A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced Monday.In two Phase 3 trials, researchers tested an oral form of sem...
Read more »

Pharmaceutical news



U.S. Faces Continuing Maternal and Infant Health Crisis
Higher Blood Pressure in Teens Tied to Later Risk for Atherosclerosis
Smoking Cannabis Tied to Less Subsequent Alcohol Consumption
RSNA: Deep Learning Model Has Identified Imaging Biomarker for Chronic Stress
Cardiac Screening Tools Fail to Identify Many Patients at Risk
Gas-Permeable Lenses Beneficial After Congenital Glaucoma Surgery
Discontinuing GLP-1 Receptor Agonist Use Before Pregnancy Tied to Risk for Adverse Outcomes
Long-Term Exposure to Black Carbon Linked to Risk for Asthma, COPD
Myelodysplastic Syndromes Tied to Incident Cardiovascular Disease
Prenatal Exposure to Metal Mixture Linked to Childhood Allergic Symptoms
Chronic Pruritus Prevalent Among Older Adults
Cannabis Cuts Alcohol-Associated Liver Disease in Patients With Alcohol Use Disorder
Investing in Nurses Reduces Physician Burnout
Most Preschoolers Aren’t Getting Enough Daily Exercise, Study Finds
Desktop versie